

| Corresponding author(s):   | Sibao Wang   |
|----------------------------|--------------|
| Last updated by author(s): | Aug 23, 2019 |

## **Reporting Summary**

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

| _  |    |    |    |     |
|----|----|----|----|-----|
| Ç. | ŀο | t۱ | ct | icc |

| Juliani  | ري<br>د  |  |  |  |  |
|--|--|--|--|--|--|
| For all statis   | stical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.   |  |  |  |  |
| n/a Confirr  | Confirmed  |  |  |  |  |
| ☐ X The  | $oxed{oxed}$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement   |  |  |  |  |
| ☐ X A S  | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly  |  |  |  |  |
| □ X The  | The statistical test(s) used AND whether they are one- or two-sided  Only common tests should be described solely by name; describe more complex techniques in the Methods section.  |  |  |  |  |
| ∑ A c  | A description of all covariates tested   |  |  |  |  |
| ∑ A c  | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons  |  |  |  |  |
| □ × Af   | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |  |  |  |  |
| ☐ ☐ For  | For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.                        |  |  |  |  |
| For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings                       |  |  |  |  |  |
| For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |  |  |  |  |  |
| Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i> ), indicating how they were calculated           |  |  |  |  |  |
| Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.                  |  |  |  |  |  |
| Software and code  |  |  |  |  |  |
| Policy inforn  | mation about <u>availability of computer code</u>  |  |  |  |  |
| Data colle   | action N/A   |  |  |  |  |
| Data analy   | wsis miRCat2(http://srna-workbench.cmp.uea.ac.uk/mircat2/), PITA (version 6), DESeq2 (version 1.14.1), miRanda (version aug2010), microtar (version 0.9.6), GraphPad Prism (version 5.00)  |  |  |  |  |

## Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers.

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

All data needed to understand and access the conclusions of this research are available in the main text and supplementary materials. The sequencing datasets were deposited in the National Center for Biotechnology Information Sequence Read Archive (accession: PRJNA517599).

| Field-specific reporting  |   |   |  |  |  |
|---------------------------|---|---|--|--|--|
| Please select the or      | ne below that is  | s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.  |  |  |  |
| ∑ Life sciences           | ∑ Life sciences           ☐ Behavioural & social sciences           ☐ Ecological, evolutionary & environmental sciences |   |  |  |  |
| For a reference copy of t | the document with   | all sections, see <a href="mailto:nature.com/documents/nr-reporting-summary-flat.pdf">nature.com/documents/nr-reporting-summary-flat.pdf</a>  |  |  |  |
|                           |   |   |  |  |  |
| Life scier                | nces stu  | udy design  |  |  |  |
| All studies must dis      | sclose on these   | points even when the disclosure is negative.  |  |  |  |
| Sample size               |   | No statistical method was used to pre-determine sample sizes. Samples sizes for small RNA-seq were about 50 infected mosquitoes from two biological replicates per time point. Sample sizes for qRT-PCR were 3 biological replicates, and were chosen to achieve reasonable estimates of variation. |  |  |  |
| Data exclusions           | No data were e  | data were excluded  |  |  |  |
| Replication               | All replications  | All replications gave similar data  |  |  |  |
| Randomization             | Mosquitoes of s   | Mosquitoes of same eclosion time were separated into different groups randomly in bioassay test.  |  |  |  |
| Blinding                  | Blinding was no   | t relevant to this study.   |  |  |  |
|                           |   |   |  |  |  |
| D = 15 = 15 to            | _ £   |   |  |  |  |
| ·                         | <u> </u>  | pecific materials, systems and methods  |  |  |  |
|                           |   | about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.                                      |  |  |  |
| Materials & exp           | perimental s  | vstems Methods  |  |  |  |
| n/a Involved in th        | ·   | n/a Involved in the study   |  |  |  |
| Antibodies                |   | ChIP-seq  |  |  |  |
| Eukaryotic                | cell lines  | Flow cytometry  |  |  |  |
| Palaeontol                | ogy   | MRI-based neuroimaging  |  |  |  |
| Animals an                | d other organism  | us  |  |  |  |
|                           | earch participant   | S   |  |  |  |
| Clinical dat              | a   |   |  |  |  |
| Antibodies                |   |   |  |  |  |
| Antibodies used           | Ag  | Ago1 antibody was a custom-made antibody by GenScript company.  |  |  |  |
| Validation                | As  | AsAGO1 antibody specificity was validated in Supplementary Figure 12.   |  |  |  |
|                           |   |   |  |  |  |
| Eukaryotic c              | ell lines   |   |  |  |  |
| Policy information        | about <u>cell lines</u>   |   |  |  |  |
| Cell line source(s)       | )   | Aedes albopictus C6/36 cells (ATCC), Homo sapiens 293T (ATCC), Drosophila melanogastor S2 cells (Thermo Fisher Scientific).   |  |  |  |
| Authentication            |   | No authentication has been used.  |  |  |  |

Cell lines were not contaminated by mycoplasma.

No cell lines used are listed in the database of commonly misidentified cell lines.

Mycoplasma contamination

Commonly misidentified lines

(See <u>ICLAC</u> register)